Check Cap Ltd (NASDAQ:CHEK) Given $10.00 Consensus Target Price by Brokerages

Shares of Check Cap Ltd (NASDAQ:CHEK) have received an average broker rating score of 1.50 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

Brokers have set a twelve-month consensus price objective of $10.00 for the company and are anticipating that the company will post ($0.43) EPS for the current quarter, according to Zacks. Zacks has also given Check Cap an industry rank of 75 out of 256 based on the ratings given to related companies.

Several research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Check Cap in a report on Wednesday, July 10th. Zacks Investment Research raised shares of Check Cap from a “sell” rating to a “hold” rating in a research report on Friday, May 17th.

An institutional investor recently raised its position in Check Cap stock. Renaissance Technologies LLC boosted its stake in Check Cap Ltd (NASDAQ:CHEK) by 24.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 307,468 shares of the medical research company’s stock after purchasing an additional 60,026 shares during the period. Renaissance Technologies LLC owned approximately 19.16% of Check Cap worth $652,000 at the end of the most recent reporting period.

Check Cap stock traded up $0.12 during trading on Friday, reaching $2.11. The company had a trading volume of 74,558 shares, compared to its average volume of 195,552. Check Cap has a 12-month low of $1.62 and a 12-month high of $4.36. The stock’s 50 day moving average price is $2.00 and its two-hundred day moving average price is $2.29. The firm has a market capitalization of $3.39 million and a price-to-earnings ratio of -0.81.

Check Cap (NASDAQ:CHEK) last released its quarterly earnings data on Wednesday, August 7th. The medical research company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.05. Equities analysts expect that Check Cap will post -1.66 earnings per share for the current year.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

See Also: Rule of 72

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.